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Background: Healthcare-utilization data for multiple sclerosis (MS) are scarce in Germany. The Purpose of the study
was to analyse administrative prevalence of MS, medication use and type of specialists involved in MS treatment in
the outpatient setting in Bavaria.
Methods: Pseudonymized claims data from Bavarian Statutory Health Insurance (SHI)-accredited physicians were
used. Administrative prevalence of MS was defined as having ≥1 MS diagnosis (International Classification of Diseases,
10th edition, code G35) documented by a neurologist or psychiatrist, or ≥1 prescription for disease-modifying drugs
(DMDs)). The administrative prevalence calculated for Bavaria was projected to Germany. DMD prescription
and involvement of different specialities in health care service for MS patients was analysed.
Results: Administrative prevalence of MS in Bavaria increased from 0.123% to 0.175% of insured persons
between 2005 and 2009; when projected, this yielded ~102,000–143,000 patients with MS in the German
population. The percentage of patients receiving ≥1 DMD prescription increased from 45.5% to 50.5%.
Patients with MS were mainly treated by neurologists in the ambulatory care setting.
Conclusions: These results provide important information on the administrative prevalence of MS in Bavaria
and on healthcare provision for patients, which is relevant for resource planning in the healthcare sector.Background
Multiple sclerosis (MS) is a chronic immune-mediated
demyelinating disease of the central nervous system
(CNS) and represents a major cause of neurological dis-
ability in young adulthood [1,2]. The estimated prevalence
of MS in Europe over the past three decades is 83 cases per
100,000, with higher rates in northern countries, and the
mean annual incidence is 4.3 per 100,000 [3,4].
In Germany, MS prevalence data vary between studies
depending on several factors, including study popula-
tion, region and methodology used. There are an esti-
mated 100,000 to 140,000 patients with MS in Germany
[5,6], with an average age at diagnosis of 35 years, and
diagnosis is 2.5 times more frequent in women than
in men [7,8]. In 80% of cases, the disease starts with a* Correspondence: ah@iges.de
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reproduction in any medium, provided the orrelapsing–remitting course, and some of these patients
will develop secondary progressive MS (SPMS) [9,10].
According to data from the German MS registry (2007),
55% of German patients suffer from relapsing–remitting
MS (RRMS), 32% from SPMS and 9% from primary pro-
gressive MS (PPMS) [7].
The socio-economic impact of MS is high. In a 2006
German cost-of-illness analysis, the mean total annual
cost of MS per patient was calculated as ~ €40,000, with
costs increasing significantly with disease severity [8].
Two-fifths of the total cost are related to decreased
productivity owing to sick leave and early retirement,
while mean direct healthcare costs are €17,165, demon-
strating that MS is a major healthcare burden in Germany
[8]. Disease-modifying drugs (DMDs), especially interferon
(IFN) beta, glatiramer acetate (GA) and natalizumab,
account for the majority of direct costs. In addition, ac-
companying symptoms and conditions such as muscle
spasms, fatigue, acute and chronic pain, depression ord. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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therapy and neurorehabilitation.
In 2001, standardized MS diagnostic criteria based on
clinical, laboratory and radiological findings (McDonald
criteria) were first published [11]. These criteria and
their subsequent revisions [12,13] simplified the diagnostic
process and contributed towards an earlier diagnosis of
MS, in particular enabled by the use of magnetic resonance
imaging (MRI) of the CNS, which allows detection of char-
acteristic abnormalities that are found in >95% of patients
[14]. Nonetheless, despite these improvements, the time to
diagnosis is still ~3 years in Germany, suggesting that there
are deficits in healthcare provision [7,8].
The German MS registry [7], which was established in
2001, provides valuable information about patient char-
acteristics and healthcare patterns in Germany. However,
the data are not representative of the MS population in
Germany owing to the fact that only a limited number
of medical centres have participated in the registry and
the proportion of rehabilitation centres with more severe
cases of MS is high. In this study, we analysed insurance
claims data from the outpatient care setting in Bavaria,
Southern Germany, with the aim of providing further
information on the administrative prevalence of MS, pre-
scribed medications and medical specialties that are mainly
involved in providing ambulatory healthcare for MS.
Methods
Data
Claims data from the Bavarian Association of Statutory
Health Insurance Physicians (BASHIP) covering the
period from 1 April 2005 to 31 December 2009 were
used. These data covered about 10.4 m insured persons
[15]. The total population of Bavaria counted 12.5 m
people [16]. Thus, about 83% of the total Bavarian popula-
tion were covered by the data. Available data were pseudo-
nymized, and included patient age and sex, prescription
details (active component, prescription month, specialty of
the prescribing physician, dosage, number of packages and
dosage forms) and details of ambulatory treatment cases
(diagnoses according to the International Classification of
Diseases, 10th edition [ICD-10], specialty of the attending
physician and fee schedule item specification and number).
The data covered all healthcare services delivered by
BASHIP office-based physicians, and approximately 98% of
drugs prescribed by BASHIP physicians reimbursed within
the statutory health insurance (SHI) system.
The claims data have been collected for the purpose of
reimbursing health care services and prescriptions by
the SHI. The use of claims data beyond this purpose, e.g.
for research, or to counsel SHI physicians is in accord-
ance to § 300 of the German Social Security Code V
(SGB V). This article rules the billing of drugs which
have been dispensed by pharmacies and are reimbursedby the SHI. The pharmacies are allowed to task computing
centers with the billing. On demand of the Associations of
Statutory Health Insurance Physicians (Kassenärztliche
Vereinigung, KV), the computing centers make avail-
able these claims data to the KV for the performance of
their tasks according to § 73 article 8, § 84, and § 305
of SGB V. § 73 article 8 is related to the coverage of
cost-effective prescribing, § 84 is related to the negoti-
ations of drug budgets between the SHI and the KV,
and § 305 says, that the KV counsels their SHI physi-
cians concerning the delivered health services [17].
The claims data used for this analysis is not publicly
available. Data analysis for the purpose of scientific in-
vestigations can be conducted in cooperation with the
BASHIP [18].
Selection of patients and administrative prevalence
Patients with MS were defined as having ≥1 diagnosis
of MS (ICD-10 code G35) in the ambulatory care set-
ting or ≥1 prescription for IFN beta-1a, IFN beta-1b,
GA or natalizumab within the observation period.
Only diagnoses by specialized physicians (Nervenärzte
[i.e. multidisciplinary specialists in both neurology and
psychiatry], neurologists and psychiatrists) were con-
sidered. For each patient and year, the first diagnosis
(index diagnosis) was counted. Patients were identified
based on their insurance number, which remains fixed
during a period of insurance with a particular provider,
but can change, for example in the case of marriage,
retirement or health-insurance mergers. If patients re-
ceived a new insurance number during the observation
period, multiple counting may have occurred and can-
not be eliminated because the required information is
lacking.
Drugs
The following DMDs were considered in detail: IFN
beta-1a, IFN beta-1b, GA, mitoxantrone and natalizumab.
Agents for symptomatic relief were grouped according to
the German Association of Neurologists guidelines for the
diagnosis and treatment of MS [9]: anti-dementia drugs,
anti-depressants, anti-epileptics, selected muscle relaxants
(baclofen, botulinum toxin, dantrolene, tizanidine, tol-
perisone, tetrazepam), urinary anti-spasmodics, selected
medications to manage fatigue (amantadine, fampridine,
modafinil), selected drugs for sexual dysfunction (sil-
denafil, tadalafil, tibolone) and selected drugs against
tremor (propranolol).
Data analysis
The administrative prevalence of MS was calculated
based on the number of identified patients (differenti-
ated by age group and sex) and the total Bavarian SHI
population between 2005 and 2009. The prevalence was
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German population using statistical data from the Min-
istry of Health (number of SHI beneficiaries) [15] and
from the Federal Statistical Office (total number of Ger-
man residents) [16] for those years. From the BASHIP
data, sex- and 5-year-age-group-specific prevalence was
applied. Confidence intervals for administrative prevalence
in the SHI population were calculated as Clopper-Pearson
intervals. The Poisson distribution was used instead of the
binomial distribution to derive cumulative probabilities, be-
cause the total number of patients in the SHI population
was unknown.
For the analysis of drug and healthcare-service utilization,
descriptive analyses were performed.
Results
Patient characteristics and prevalence of MS in Bavaria
and Germany
During the observation period, 30,400 patients with MS
were documented by office-based specialists of the
Bavarian Association of Statutory Health Insurance Phy-
sicians (BASHIP). The number of patients identified an-
nually ranged between 12,836 (2005) and 18,183 (2009).
Owing to multiple counting in cases where the insur-
ance number had changed or there was migration into
or out of the Bavarian outpatient sector, the sum of the
annual number of patients differed from the total num-
ber of patients.Table 1 Administrative prevalence of MS
Bavaria (SHI population)
Year Sex Patients with MS Administrative prevalence Pat
n1 % (95% CI)
2005 Men 3,361 0.069 (0.067; 0.072)
Women 9,465 0.17(0.167; 0.174)
All 12,826 0.123(0.121; 0.126)
2006 Men 3,773 0.078(0.076; 0.081)
Women 10,579 0.191(0.187; 0.194)
All 14,352 0.138(0.136; 0.14)
2007 Men 4,053 0.084(0.081; 0.086)
Women 11,453 0.206(0.202; 0.21)
All 15,506 0.149(0.147; 0.152)
2008 Men 4,494 0.093(0.09; 0.095)
Women 12,381 0.223(0.219; 0.227)
All 16,875 0.162(0.16; 0.164)
2009 Men 4,857 0.1(0.097; 0.103)
Women 13,319 0.24(0.236; 0.244)
All 18,176 0.175(0.172; 0.177)
Based on data from the SHI system in Bavaria and estimated administrative prev
CI = confidence interval; MS =multiple sclerosis; SHI = Statutory Health Insurance.
1Patients of unknown sex were not considered for the estimation of prevalence. Th
2008 and 2009, respectively, resulting in a total number of 12,836, 14,361, 15,511, 1The total administrative prevalence of MS in Bavaria
(SHI population) increased from 0.123% in 2005 to
0.175% in 2009 (Table 1). The projection of this preva-
lence to the total German population resulted in esti-
mated numbers of 101,702 and 142,856 patients with
MS in 2005 and 2009, respectively. Of all identified pa-
tients in the Bavarian SHI population (n = 30,400), 73.1%
(n = 22,226) were women (sex was unknown for 0.12%
[n = 36] of patients), 44.0% (n = 13,387) were 30–44
years old, and 28.5% (n = 8,654) were 45–59 years old.
The median (standard deviation [SD]) observation time
was 1469 (567) days, and for 50.3% of patients the obser-
vation period lasted >4 years.
Frequency and differentiation of MS diagnoses
The German modification of ICD-10 comprises five MS
diagnoses: G35.0 (first manifestation), G35.1 (RRMS),
G35.2 (PPMS), G35.3 (SPMS) and G35.9 (not specified).
For most patients, the index diagnosis was G35.9 (Figure 1);
however, ICD-10 diagnoses increased from 25.9% in 2005
to 36.3% in 2009 for RRMS, and from 4.9% to 7.5% for
SPMS. In 2009, RRMS was the most often documented
diagnosis for patients aged <40 years (3978/9451 [42.1%]),
whereas in patients aged ≥40 years, SPMS was the
most frequent (3514/8732 [40.2%]). PPMS was mainly
documented for patients ≥50 years of age (559/3512
patients [15.9%]). In each year, a small number of iden-
tified patients had no MS diagnosis recorded (2005:Germany
ients with MS, SHI population Patients with MS, total population
n (95% CI) n (95% CI)
22,865(22,098; 23,651) 28,030(27,090; 28,994)
63,471(62,198; 64,762) 71,672(70,235; 73,131)
86,589(85,097; 88,101) 101,702(99,949; 103,477)
25,634(24,823; 26,466) 31,450(30,455; 32,470)
70,810(69,467; 72,173) 80,049(78,531; 81,589)
96,737(95,161; 98,333) 113,734(111,881; 115,611)
27,524(26,684; 28,385) 33,723(32,693; 34,778)
76,592(75,195; 78,008) 86,473(84,897; 88,072)
104,444(102,807; 106,102) 122,636(120,713; 124,581)
30,419(29,536; 31,322) 37,189(36,109; 38,292)
82,585(81,136; 84,052) 93,130(91,497; 94,786)
113,336(111,633; 115,059) 132,860(130,863; 134,880)
32,786(31,870; 33,721) 40,121(39,000; 41,265)
88,619(87,120; 90,137) 100,014(98,323; 101,728)
121,754(119,991; 123,537) 142,856(140,786; 144,948)
alence in Germany (SHI and total populations).
ere were 10, 9, 5, 5 and 7 patients of unknown sex in 2005, 2006, 2007,
6,880 and 18,183 patients identified each year.
Figure 1 Patient distribution according to multiple sclerosis index diagnosis for the years 2005–2009. PPMS = primary progressive
multiple sclerosis; RRMS = relapsing–remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis.
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Prescription of DMDs
The proportion of patients with ≥1 DMD prescription
increased from 45.5% in 2005 to 50.5% in 2009. The
highest percentage of prescriptions was found amongFigure 2 Percentage of patients with prescriptions for DMDs, by m
disease-modifying drug; PPMS = primary progressive multiple sclerosis; R
progressive multiple sclerosis.patients with a diagnosis of RRMS, which rose from
52.6% to 58.6% (Figure 2). The proportion of patients
with DMD prescriptions increased from 43.2% to 49.9%
in patients with a first manifestation, and from 40.0% to
46.9% in those with a non-specified MS diagnosis. In the
different age groups, the following increases in the pro-
portions of patients with prescriptions were observedultiple sclerosis index diagnosis during 2005–2009. DMD,
RMS = relapsing–remitting multiple sclerosis; SPMS = secondary
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tients <30 years of age, from 53.2% to 59.4% in patients
aged 30–44 years, from 36.9% to 45.4% in patients aged
45–59 years, and from 17.2% to 18.5% in patients
aged ≥60 years.
Most patients received prescriptions for IFN beta-1a
and IFN beta-1b, although these rates decreased between
2005 and 2009, from 51.6% to 48.3% and from 22.4% to
19.9%, respectively. Conversely, the percentage of pa-
tients with GA prescriptions increased from 18.6% to
23.7%. Natalizumab, available in Germany since 2006,
was prescribed for 7.0% of patients in 2009.
DMD prescriptions were mainly issued by specialized
physicians. In 2009, 85.7% of IFN beta-1a prescriptions,
87.6% of IFN beta-1b prescriptions, 87.9% of GA pre-
scriptions and 91.6% of natalizumab prescriptions were
issued by Nervenärzte or neurologists.
Drugs for symptomatic relief
The number of patients with prescriptions for symptom-
atic therapy increased from 4,938/12,836 (38.5%) in 2005
to 7,380/18,183 (40.6%) in 2009. In 2009, the most often
prescribed drug was baclofen (9% of patients), followed
by citalopram (8.0%), gabapentin (4.9%), tolperisone (4.2%)
and mirtazapine (3.6%). Nervenärzte (36.0%) or neurolo-
gists (18.3%) filled most prescriptions. Prescriptions for
NSAIDs were documented for 33.4% of patients and were
mainly written by general practitioners (58.6%). Hypnotics
and sedatives, opioids and neuroleptics were prescribed in
11.8%, 7.1% and 3.7% of cases, respectively. Prescriptions
for corticosteroids for systemic use were recorded for
29.9% of patients and were mostly compiled by Nervenärzte
(37.8%) or neurologists (28.7%).
MRI of the neurocranium or spinal cord
The only diagnostic measure that is specific for MS and
is specified by the fee schedule valid for German SHI
physicians is MRI of the neurocranium or spinal cord
(neuro-MRI). In 2005 (data for April to December only),
24.7% of patients underwent neuro-MRI scanning. After
that, the percentage of patients for whom this diagnostic
measure was used increased from 32.1% in 2006 to 33.6%
in 2009, and was higher in patients receiving DMDs. In
2009, neuro-MRI scans were performed in 41.2% of pa-
tients with DMD prescriptions versus 29.2% of those with-
out prescriptions. Similar differences were seen for all other
years, including 2005 (data not shown).
Discussion
The main objective of this analysis was to provide infor-
mation on the epidemiology of MS and healthcare
utilization in patients with MS in Germany, using claims
data from SHI-accredited physicians in Bavaria.Patient characteristics were consistent with previous
publications [1,7]: women were almost three times more
likely than men to have MS, and the most affected age
group was 30 to <60 years, suggesting that MS mainly
concerns the working-age population.
In Bavaria, the number of patients with MS increased
by 41.7% between 2005 and 2009. Projected patient
numbers calculated for Germany based on these data
(101,702 in 2005 and 142,856 in 2009) fit with observa-
tions from other German epidemiological studies that
report a range of 100,000–140,000 patients with MS
[5,6]. The exact reasons for the increase in MS adminis-
trative prevalence are not known, but it should be
taken into account that there were major revisions of
the MS diagnostic criteria during the observation
period [19], which may have allowed an earlier diagno-
sis (at the time of the first demyelinating event or
clinically isolated syndrome [CIS]) and simplified the
diagnostic process through the use of MRI. In addition,
the capacity to perform MRI scans has increased
substantially in Germany over the last 10 years, which,
combined with the revisions in diagnostic criteria,
could have led to an increase in the number of diag-
noses made. Although the current analysis is not
directly comparable with population-based epidemio-
logical studies, the results are consistent with a
meta-analysis that showed that the prevalence and
incidence of MS generally increased over the last
three to six decades, especially in women [20]. It is
not possible to indicate the extent to which the ob-
served increase in administrative MS prevalence is
due to an actual increase.
There was a difference in the number of patients who
were identified annually compared to the number of MS
patients counted during the total observation period.
The difference between the annual count and the total
count is due to different factors, e.g. migration between
the German states. But the main reason is double count-
ing because the insurance number of the patient – by
which the patients are identified – changes (for reasons
see Methods). It is not possible to specify the exact
proportion of patients, who have been counted twice
or more. There is also no information, if there may be
differences in the proportion of double counting con-
sidering morbidity, age, or sex. A crude estimation of
the proportion of patients can be made considering the
difference between the annual patient numbers and the
total numbers as well as the number of years. This
estimation indicates about 13% of the patients with pos-
sible double counting. Taking this possible double count-
ing in consideration, the administrative MS prevalence
calculated from the data of this analysis is probably over-
estimated. It can be expected that the true prevalence is
about 10% lower.
Höer et al. BMC Health Services Research 2014, 14:381 Page 6 of 7
http://www.biomedcentral.com/1472-6963/14/381As the majority of patients had a non-specified diag-
nosis of MS (ICD-10 code G35.9), our data provide only
partial information on the frequency of the different MS
subtypes in Bavaria. However, the results are consistent
with existing studies showing that the majority of MS
cases begin with a relapsing–remitting course, which
may evolve into a secondary progressive course. If un-
treated, ~50% of patients develop SPMS within 10 years
[9,10]. The decrease in use of the diagnosis codes G.35.0
(first manifestation) and G35.9 (not specified), and
increase in use of the more specific diagnosis codes
(G35.1, G35.2 or G35.3), suggest that new patients are
more often diagnosed with specific codes.
The percentage of patients who received ≥1 DMD pre-
scription increased over the years (45.5% in 2005 to
50.5% in 2009). IFN beta-1a and IFN beta-1b were the
most frequently prescribed drugs, accounting for over
two-thirds of prescriptions, while prescriptions for GA
increased to almost one-quarter of the total by 2009.
These results are consistent with a similar analysis of
claims data from the largest German SHI (8.8 million
beneficiaries) that reported an increase in DMD pre-
scriptions in the German MS population from 33.3% in
2004 to 40.9% in 2008, the majority being prescriptions
for IFN beta [21]. These percentages are lower compared
with data from the German MS registry, which reported
that 71% of patients with MS received DMDs during 2005–
2006; however, a high proportion of patients covered by the
MS registry are treated in rehabilitation and specialized
medical centres and require drug treatment [7].
An increase in DMD prescriptions was also observed
in a Canadian study that had analysed population data
from International Medical Statistics Health for 2002–
2007 and reported a rise in DMD prescriptions by
approximately 30% [22]. The increase observed in
Germany followed a revision of the MS guidelines in
2006 that introduced major changes [19], such as rec-
ommendations for early DMD treatment at the time of
the first demyelinating event or CIS, use of MRI to facili-
tate diagnosis and early treatment, and prolonged treat-
ment with DMDs based on long-term efficacy and safety
data for IFN beta.
Our analysis found that the percentage of patients with
relevant MRI scans (neurocranium or spinal cord) was
substantially higher in patients treated with DMDs; this
is probably due to the fact that MRI scans are used in
these patients to assess whether brain and spinal cord le-
sions are reduced by DMD use. Finally, the study
showed that Nervenärzte and neurologists are the spe-
cialists most involved in the medical treatment of pa-
tients with MS within the office-based sector, which is in
accordance with MS guidelines stating that the neurolo-
gist is the responsible physician for differential diagnosis,
treatment initiation and follow-up.This study is subject to certain limitations. The infor-
mation available for the diagnosis of MS did not include
any clinical measures such as MRI scans or laboratory
parameters; therefore data quality relied solely on the
diagnosis and prescriptions made by physicians. The
criteria on which physicians based their decisions remain
unknown. The data base includes data from all members
of the SHI in Bavaria, which means that 83% of the total
Bavarian population are covered (see Methods). There-
fore, the data reflect the MS prevalence and health care
referring to the great majority of the Bavarian popula-
tion, although it cannot be excluded that there are some
differences compared to the part of the population with-
out access to the health care services covered by the
SHI. Furthermore, the SHI population of Bavaria may
differ from the overall German population in terms of
demographic characteristics and/or morbidity. For this
reason, age-group- and sex-specific prevalence was used
for the projection of the numbers onto the German
population. It is also possible that physicians in Bavaria
differ in their prescribing and diagnostic behaviour
owing to different incentives set by the regional associ-
ation of SHI-accredited physicians for reporting medical
procedures. Finally, the data cover only patients who
had already received a diagnosis or treatment for MS.
Patients without a diagnosis or MS-specific treatment (e.
g. patients with very inactive MS who have not received
medical attention or treatment during the time period
surveyed) were not included, possibly underestimating
the prevalence of MS. On the other hand, it was not
possible to identify cases in which the initial diagnoses
of MS were incorrect. This may result in a slight over-
estimation of the prevalence of MS.
Conclusions
Our study shows that the administrative prevalence of
MS in Germany has increased in recent years. Owing to
the availability of new oral drugs that will lead to an in-
crease in the number of treated patients, a further rise in
administrative prevalence can be expected in the future.
A growing proportion of patients receive DMDs, in par-
ticular IFN beta, although the use of GA is increasing.
Ambulatory healthcare services for patients with MS are
delivered mainly by specialized physicians.
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